论文部分内容阅读
目的:评价恩替卡韦对慢性乙型肝炎(CHB)患者初治的近期疗效,为临床合理用药提供参考。方法:将68例CHB患者随机分为两组,每组34例,以接受拉米夫定治疗者为A组,以接受恩替卡韦治疗者为B组;评价两组患者治疗6周后ALT、AST、GGT及HBV-DNA含量改善情况,并对接受3月治疗后两组HBV-DNA转阴率作一对比。结果:治疗6周后B组患者ALT、AST、GGT及HBV-DNA含量显著优于A组(P<0.05);B组患者治疗3月后HBV-DNA阳性率显著低于A组(P<0.05)。结论:恩替卡韦可有效地提高CHB患者的近期疗效。
Objective: To evaluate the short-term curative effect of entecavir on initial treatment in patients with chronic hepatitis B (CHB) and to provide a reference for clinical rational drug use. Methods: Sixty-eight CHB patients were randomly divided into two groups with 34 cases in each group. The patients receiving lamivudine were group A and the patients receiving entecavir were group B. The levels of ALT, AST , GGT and HBV-DNA content, and to compare the negative rate of HBV-DNA in two groups after receiving treatment in March. Results: After 6 weeks of treatment, the levels of ALT, AST, GGT and HBV-DNA in group B were significantly better than those in group A (P <0.05); The positive rate of HBV-DNA in group B was significantly lower than that in group A 0.05). Conclusion: Entecavir can effectively improve the short-term efficacy of CHB patients.